CG Oncology to Participate in the 120th American Urological Association Annual Meeting with a Series of Key Presentations and Updates
- Durability Results from BOND-003 data will be presented as a late breaker as part of AUA's Practice- changing, Paradigm-shifting Clinical Trials in Urology - - Additional updates from across CG Oncology's clinical trial program, including translational data, planned - Location: Venetian Ballroom, The Venetian Convention & Expo Center IP02-28: Translational Correlates using Urinary Genomic Disease Burden to Assess Cretostimogene Grenadenorepvec: Updated Analysis from the BOND-003 and CORE-001 Trials Sessio ...